Pharsight

Banzel patents expiration

BANZEL Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(10 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(4 months ago)

Banzel is owned by Eisai Inc.

Banzel contains Rufinamide.

Banzel has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Banzel are:

  • US6740669*PED
  • US6740669

Banzel was authorised for market use on 03 March, 2011.

Banzel is available in suspension;oral dosage forms.

The generics of Banzel are possible to be released after 14 May, 2023.

Drugs and Companies using RUFINAMIDE ingredient

Market Authorisation Date: 03 March, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of BANZEL before it's drug patent expiration?
More Information on Dosage

BANZEL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic